(NAMS) NewAmsterdam Pharma - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 4.178m USD | Total Return: 93.9% in 12m
Avg Turnover: 41.6M
Warnings
Beneish M-Score 1.00 > -1.5 - likely earnings manipulation
Altman Z'' -12.66 < 1.0 - financial distress zone
Choppy Below Avwap Earnings
Tailwinds
Confidence
NewAmsterdam Pharma Company N.V. (NAMS) is a Netherlands-based biopharmaceutical firm focused on developing oral therapies for cardiometabolic and neurodegenerative diseases. The company’s primary candidate is obicetrapib, a low-dose cholesteryl ester transfer protein (CETP) inhibitor currently in late-stage clinical trials for LDL-cholesterol reduction and Phase 2a trials for Alzheimer’s disease.
The biotechnology sector often utilizes CETP inhibition to address unmet needs in cardiovascular care, particularly for patients who are intolerant to statins or require additional lipid-lowering efficacy. As a late-stage developer, the company’s valuation is heavily tied to the clinical success and regulatory approval timelines of its monotherapy and combination treatments.
Investors should review ValueRay for further data on the companys clinical pipeline and market position.
- Obicetrapib Phase 3 clinical trial results determine long-term commercial viability and valuation
- FDA and EMA regulatory approvals for LDL-C reduction drive market entry
- Commercial partnership agreements and milestone payments influence near-term cash runway
- Competitive landscape of PCSK9 inhibitors impacts future market share and pricing
- Expansion into Alzheimers treatment indications provides secondary long-term growth catalyst
| Net Income: -212.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.19 > 0.02 and ΔFCF/TA -2.21 > 1.0 |
| NWC/Revenue: 2.62k% < 20% (prev 1.65k%; Δ 970.4% < -1%) |
| CFO/TA -0.19 > 3% & CFO -141.9m > Net Income -212.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 9.76 > 1.5 & < 3 |
| Outstanding Shares: last quarter (121.1m) vs 12m ago 4.29% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 2.91% > 50% (prev 5.76%; Δ -2.85% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.81 (Total Current Assets 658.0m - Total Current Liabilities 67.4m) / Total Assets 732.6m |
| B: -1.11 (Retained Earnings -810.8m / Total Assets 732.6m) |
| C: -0.30 (EBIT TTM -232.0m / Avg Total Assets 775.5m) |
| D: -11.75 (Book Value of Equity -792.0m / Total Liabilities 67.4m) |
| Altman-Z'' = -12.66 = D |
| DSRI: 10.65 (Receivables 8.22m/1.61m, Revenue 22.6m/47.1m) |
| GMI: 1.03 (GM 97.04% / 99.85%) |
| AQI: 165.1 (AQ_t 0.10 / AQ_t-1 0.00) |
| SGI: 0.48 (Revenue 22.6m / 47.1m) |
| TATA: -0.10 (NI -212.7m - CFO -141.9m) / TA 732.6m) |
| Beneish M = 101.8 (Cap -4..+1) = D |
As of May 24, 2026, the stock is trading at USD 35.74 with a total of 1,039,448 shares traded.
Over the past week, the price has changed by +0.00%,
over one month by +10.96%,
over three months by -2.02% and
over the past year by +93.87%.
NewAmsterdam Pharma has received a consensus analysts rating of 4.56. Therefore, it is recommended to buy NAMS.
- StrongBuy: 5
- Buy: 4
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 50.1 | 40% |
P/B = 6.2738
Revenue TTM = 22.6m USD
EBIT TTM = -232.0m USD
EBITDA TTM = -231.8m USD
Long Term Debt = unknown (0.0)
Short Term Debt = 23.0k USD (from shortTermDebt, last quarter)
Debt = 23.0k USD (from shortLongTermDebtTotal, last quarter) (leases 23.0k already included)
Net Debt = -636.1m USD (calculated: Debt 23.0k - CCE 636.1m)
Enterprise Value = 3.54b USD (4.18b + Debt 23.0k - CCE 636.1m)
Interest Coverage Ratio = unknown (Ebit TTM -232.0m / Interest Expense TTM 0.0)
EV/FCF = -24.91x (Enterprise Value 3.54b / FCF TTM -142.2m)
FCF Yield = -4.01% (FCF TTM -142.2m / Enterprise Value 3.54b)
FCF Margin = -630.1% (FCF TTM -142.2m / Revenue TTM 22.6m)
Net Margin = -942.8% (Net Income TTM -212.7m / Revenue TTM 22.6m)
Gross Margin = unknown ((Revenue TTM 22.6m - Cost of Revenue TTM 668k) / Revenue TTM)
Tobins Q-Ratio = 4.83 (Enterprise Value 3.54b / Total Assets 732.6m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 23.0k)
Taxrate = 21.0% (US default 21%)
NOPAT = -183.3m (EBIT -232.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 9.76 (Total Current Assets 658.0m / Total Current Liabilities 67.4m)
Debt / Equity = 0.00 (Debt 23.0k / totalStockholderEquity, last quarter 665.2m)
Debt / EBITDA = 2.74 (negative EBITDA) (Net Debt -636.1m / EBITDA -231.8m)
Debt / FCF = 4.47 (negative FCF - burning cash) (Net Debt -636.1m / FCF TTM -142.2m)
Total Stockholder Equity = 713.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -27.43% (Net Income -212.7m / Total Assets 732.6m)
RoE = -13.95% (Net Income TTM -212.7m / Total Stockholder Equity 1.52b)
RoCE = -15.22% (EBIT -232.0m / Capital Employed (Equity 1.52b + L.T.Debt 0.0))
RoIC = -27.56% (negative operating profit) (NOPAT -183.3m / Invested Capital 665.2m)
WACC = 8.89% (E(4.18b)/V(4.18b) * Re(8.89%) + D(23.0k)/V(4.18b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 8.89% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 82.22 | Cagr: 18.62%
[DCF] Fair Price = unknown (Cash Flow -142.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.48 | # QB: 0
Revenue Correlation: 46.24 | Revenue CAGR: 43.17% | SUE: 0.18 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.42 | Chg30d=+2.16% | Revisions=+23% | Analysts=12
EPS next Quarter (2026-09-30): EPS=-0.42 | Chg30d=+2.72% | Revisions=+20% | Analysts=12
EPS current Year (2026-12-31): EPS=-1.58 | Chg30d=+6.08% | Revisions=+33% | GrowthEPS=-8.9% | GrowthRev=+22.5%
EPS next Year (2027-12-31): EPS=-1.32 | Chg30d=+3.76% | Revisions=+38% | GrowthEPS=+15.3% | GrowthRev=+466.0%
[Analyst] Revisions Ratio: +38%